Atherosclerotic cardiovascular disease (ASCVD) is epidemic throughout the world and is
etiologic for such acute cardiovascular events as myocardial infarction, ischemic stroke …

Over the last 10 years, there have been advances on several aspects of lipoprotein (a)
which are reviewed in the present article. Since the standard immunoassays for measuring …

Genome wide association, epidemiological, and clinical studies have established high
lipoprotein (a)[Lp (a)] as a causal risk factor for atherosclerotic cardiovascular disease …

Lipoprotein (a) or lipoprotein “little a”[Lp (a)] is an under-recognized causal risk factor for
cardiovascular (CV) disease (CVD), including coronary atherosclerosis, aortic valvular …

Background and aims The role of Lp (a) in multi-ethnic Asian populations with coronary
artery disease (CAD) has not been well established. The aims of this study were (i) to …

Background and aims Familial hypercholesterolaemia (FH) and elevated plasma lipoprotein
(a)[Lp (a)] are inherited conditions independently associated with atherosclerotic …

For patients with lupus erythematosus (LE) or dermatomyositis (DM), there is an urgent need
to address a heightened risk of clinical events, chiefly heart attacks and strokes, caused by …

Background and aims High lipoprotein (a)[Lp (a)] plasma levels are associated with
increased atherosclerotic cardiovascular disease (ASCVD), in part attributed to elevated …

Objective Patients with lupus erythematosus (LE) are at heightened risk for clinical events,
chiefly heart attacks and strokes, from atherosclerotic cardiovascular disease (ASCVD). We …

Pathophysiological, epidemiological and genetic studies convincingly showed lipoprotein
(a)(Lp (a)) to be a causal mediator of atherosclerotic cardiovascular disease (ASCVD). This …